Aging is a gradual breakdown of every system in the body, and it raises the risk of disease and death. Among known interventions, rapamycin stands out as one of the most promising: it extends lifespan from yeast to mammals by suppressing the mTOR signaling pathway. But rapamycin acts unevenly: its effect depends on dose, timing, sex and tissue type. Until now it was unclear which cells are responsible for the lifespan extension, which stay neutral, and which might even be harmed. This work sits apart from its neighbors in the archive, but nearby lie studies of cellular aging and of loss of meaning in aging, which set the direction: from general mechanisms to a cellular map.
The researchers fed Drosophila melanogaster flies rapamycin at a dose of 20 µM, which reliably extended lifespan. They then collected heads and bodies of males and females at four ages: 7, 30, 50 and 70 days. Cell nuclei were isolated by sorting and their RNA was sequenced on the 10x Genomics platform. In total they obtained 28 libraries and 505,731 high-quality nuclei. Cell types were identified by transferring labels from previous atlases and manually checking markers. To assess aging, they trained cell-specific "clocks" on control samples and compared the predicted age after treatment.
Rapamycin produced very different changes depending on cell type. The most differentially expressed genes turned up in reproductive tissues: 7 of the 15 most responsive cell types. The fat body, enterocytes, oenocytes, ventral nerve cord and indirect flight muscles also responded strongly. Neurons and glia changed little. Expression of Fkbp12, rapamycin's cofactor, correlated positively with the number of altered genes. In aging cells a shared signature of 469 genes appeared, which they named the Convergent Aging Trajectory (CAT). CAT-high nuclei accumulated with age and declined after treatment, and in females the effect was stronger. In females rapamycin lowered the predicted age in nervous and muscle tissues, preserved the number of muscle nuclei and improved climbing. In 30-day-old males, many cell types showed a neutral or even negative response, and protection appeared later.
This work differs from its neighbors in the archive by providing the first map of rapamycin's action at the level of individual cells across the whole body. Nearby studies describe aging as a loss of meaning or a change in methylation, but do not link it to a specific drug intervention. Here it is shown that rapamycin does not hit every cell; it hits the shared CAT state that arises in different tissues. This changes how we view geroprotection: instead of hunting for a universal target, we can look for shared cellular states that are sensitive to the drug.
The topic can be developed by checking whether CAT-like states exist in mammals and humans. It is also important to measure how well rapamycin penetrates different tissues, especially the brain, to understand why neurons respond weakly. Combining this with metabolomics and proteomics will show whether CAT is the cause of metabolic drift or a consequence of adaptation to stress. Finally, one could look for other interventions that act on CAT-like states and combine them with rapamycin.
The results will influence gerontology, the pharmacology of aging and precision medicine. The Rapa-FCA atlas will become a resource for studying sex differences in drug response and for developing cell-oriented strategies to extend lifespan.
Next steps: measure the pharmacokinetics of rapamycin in different fly tissues, check for CAT in mice and humans, and test combinations of drugs that act on different aspects of CAT.
For gerontology, it remains an open question why some cells age faster than others and why interventions work selectively. This work links that to the accumulation of the shared CAT state, but does not explain what triggers its appearance. It is also unclear how universal CAT is across species and whether it can be used as a biomarker of aging in humans.
Rapamycin was discovered in a soil sample from Easter Island and named after the island's local name, Rapa Nui. Its molecule weighs 914.2 daltons, which is quite a lot for a drug, and this may be what keeps it from getting into the brain.
The idea of a shared aging state that can be suppressed by a drug echoes Aldous Huxley's novel Brave New World, where people take soma to maintain youth and stability, though in reality rapamycin does not act that totally.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.